ИНК. (US);ДЗЕ ХЕНРИ М. ДЖЕКСОН ФАУНДЕЙШН ФО ДЗЕ ЭДВЕНСМЕНТ ОФ МИЛИТЭРИ МЕДИСИН
发明人:
О'БРИН Элисон (US),МЕЛТОН-ЦЕЛЬСА Анжела (US),СМИТ Майкл (US),СИНКЛЕР Джеймс (US),ОБРИН Элисон (US)
申请号：
RU2011126896/10
公开号：
RU2011126896A
申请日:
2010.01.21
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. A composition for promoting an immune response to Stx2, comprising a pharmaceutically acceptable carrier and at least one purified polypeptide, said polypeptide comprising: (i) SEQ ID NO: 1； or (ii) SEQ ID NO: 1 and 2； or (iii) SEQ ID NO: 1, 2, and 3； and a protein framework not associated with the Shx-Toxin Stx2, wherein SEQ ID NO: 1, SEQ ID NO: 1 and 2； or SEQ ID NO: 1, 2, and 3 are inserted into said protein framework not associated with a Shx-toxin Stx2, and said polypeptide has antigenic properties of Stx2.2. The composition of claim 1, wherein said framework comprises a protein substantially identical to Stx1, or a fragment thereof. The composition of claim 1, wherein said polypeptide comprises SEQ ID NO: 1, 2, and 3 and a protein framework not associated with the Shx-toxin Stx2. The composition according to claim 1, wherein said polypeptide comprises SEQ ID NO: 1 and 2 and a protein framework not associated with the Shx-toxin Stx2. The composition of claim 1, wherein said composition does not stimulate an immune response to Stx1.6. The composition of claim 1, wherein said polypeptide comprises amino acid sequences substantially identical to the amino acid sequences of SEQ ID NO: 8.7. The composition of claim 1, wherein said polypeptide comprises the amino acid sequences listed under SEQ ID NO: 8.8. A composition for stimulating an immune response to Stx2 comprising a pharmaceutically acceptable carrier and at least one purified polypeptide comprising an amino acid sequence that is at least 92% identical to the amino acid sequence of SEQ ID NO: 8, said polypeptide having antigenic properties of Stx2.9. The composition of claim 1 or 8, wherein said composition further comprises an adjuvant. Cleared1. Композиция для стимулирования иммунного ответа на Stx2, включающая фармацевтически приемлемый носитель и по меньшей мере один очищенный полипептид, причем указанный полипептид включает:(i) SEQ ID NO:1； или(ii) SEQ ID NO:1 и 2； или(iii) SEQ ID NO:1, 2 и 3；и не ас
